13.3 Biological and Somatic Treatments: Psychotropic Medications and Neuromodulation

Biological and Somatic Treatments: Psychotropic Medications and Neuromodulation

Biological interventions in psychiatry are grounded in the medical model, conceptualizing severe psychiatric disorders as dysregulations within neurochemical signaling, synaptic plasticity, genetic expression, and functional neural circuits. Somatic treatments encompass psychopharmacology—the administration of chemical compounds that cross the blood-brain barrier to modulate neurotransmission—and neuromodulation techniques that apply electrical or magnetic stimulation directly to cortical and subcortical brain structures.

                             [ Biological & Somatic Treatments ]
                                              │
     ┌──────────────────┬─────────────────────┼─────────────────────┬──────────────────┐
     ▼                  ▼                     ▼                     ▼                  ▼
[ Antidepressants ] [ Anxiolytics ]    [ Mood Stabilizers ]  [ Antipsychotics ]  [ Neuromodulation ]
- SSRIs / SNRIs     - Benzodiazepines  - Lithium Carbonate   - Typicals (D2)     - ECT (Seizure)
- TCAs (Cardiotox)  - Barbiturates     - Valproate           - Atypicals         - rTMS (dlPFC)
- MAOIs (Tyramine)  - Buspirone        - Lamotrigine (SJS)     (D2 + 5-HT2A)     - DBS (Area 25)
- Bupropion (NDRI)                                           - Clozapine (ANC)   - VNS

1. Antidepressant Classes and Monoaminergic Pharmacology

Historically, the Monoamine Hypothesis of Depression posited that depressive pathology stems directly from an absolute depletion of monoamine neurotransmitters—specifically Serotonin ($5\text{-HT}$), Norepinephrine ($NE$), and Dopamine ($DA$)—within limbic and prefrontal synaptic clefts. However, while modern antidepressants elevate synaptic monoamine concentrations within hours of ingestion, clinical therapeutic relief requires 2 to 4 weeks of continuous administration. Modern neurobiology explains this therapeutic lag via downstream neuroplastic adaptations: chronic monoamine elevation leads to the desensitization of inhibitory presynaptic $5\text{-HT}_{1\text{A}}$ and $\alpha_2$-adrenergic autoreceptors, activation of cAMP-CREB second-messenger cascades, and upregulation of Brain-Derived Neurotrophic Factor (BDNF), which reverses stress-induced hippocampal dendritic atrophy and stimulates adult neurogenesis.

Major Antidepressant Classes

• Selective Serotonin Reuptake Inhibitors (SSRIs):
  • Compounds: Fluoxetine (longest half-life via active metabolite norfluoxetine), Sertraline, Paroxetine (highly anticholinergic and sedating), Citalopram (dose-dependent QTc prolongation risk), Escitalopram.
  • Mechanism: Selectively inhibit the presynaptic Serotonin Transporter (SERT), blocking reuptake and dramatically increasing synaptic $5\text{-HT}$ availability.
  • Adverse Effects: Gastrointestinal distress (nausea, diarrhea via stimulation of gastrointestinal $5\text{-HT}_3$ receptors), insomnia, psychomotor agitation, and high rates of sexual dysfunction (anorgasmia, delayed ejaculation, decreased libido in up to $40\text{--}50\%$ of patients via stimulation of $5\text{-HT}_2$ receptors; a primary cause of medication discontinuation). Black Box warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults ($\le 24$ years).
  • Serotonin Syndrome: A potentially fatal hyper-serotonergic toxicity occurring when serotonergic agents are combined (e.g., SSRIs + MAOIs, triptans, or St. John's Wort). Diagnosed via the Hunter Toxicity Criteria, presenting with the clinical triad of:
    1. Autonomic Hyperactivity: Diaphoresis, severe hyperthermia, tachycardia, labile blood pressure.
    2. Neuromuscular Abnormalities: Spontaneous or inducible clonus, hyperreflexia, ocular clonus, and tremors (characteristically affecting lower extremities more than upper extremities).
    3. Mental Status Changes: Agitation, confusion, delirium.
    4. Management: Immediate discontinuation of all serotonergic agents, supportive care, and administration of the $5\text{-HT}_{2\text{A}}$ antagonist Cyproheptadine.
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs):
  • Compounds: Venlafaxine, Duloxetine.
  • Mechanism: Dual inhibition of both the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET).
  • Clinical Features: Efficacious for severe depression and comorbid chronic pain conditions (diabetic neuropathy, fibromyalgia). Can produce dose-dependent elevations in diastolic blood pressure and heart rate secondary to noradrenergic peripheral tone.
• Tricyclic Antidepressants (TCAs):
  • Compounds: Imipramine, Amitriptyline, Nortriptyline.
  • Mechanism: Block reuptake of $5\text{-HT}$ and $NE$ via SERT and NET inhibition.
  • Receptor Promiscuity and Side Effects: TCAs act as antagonists across multiple off-target neuroreceptors:
    • Muscarinic Cholinergic ($M_1$) Antagonism: Severe anticholinergic side effects (dry mouth, blurred vision, urinary retention, constipation, tachycardia, cognitive delirium).
    • Histaminergic ($H_1$) Antagonism: Marked sedation, drowsiness, and weight gain.
    • Alpha-1 Adrenergic ($\alpha_1$) Antagonism: Orthostatic hypotension, dizziness, and reflex tachycardia.
  • Cardiotoxicity in Overdose: TCAs block cardiac fast voltage-gated sodium ($Na^+$) channels, prolonging intraventricular conduction, widening the QRS complex, and precipitating fatal ventricular arrhythmias (torsades de pointes, ventricular fibrillation). TCAs have an exceptionally narrow therapeutic index; a 2- to 3-week supply can be lethal in an intentional overdose.
• Monoamine Oxidase Inhibitors (MAOIs):
  • Compounds: Phenelzine, Tranylcypromine, Selegiline.
  • Mechanism: Irreversibly inhibit Monoamine Oxidase (MAO), the mitochondrial enzyme responsible for the enzymatic degradation of monoamines. $\text{MAO-A}$ preferentially metabolizes $5\text{-HT}$ and $NE$; $\text{MAO-B}$ metabolizes phenylethylamine; both metabolize dopamine.
  • The Tyramine "Cheese Reaction" (Hypertensive Crisis): Dietary tyramine (abundant in aged cheeses, cured meats, draft beer, red wine, fermented soy) is normally inactivated in the gastrointestinal tract and liver by intestinal $\text{MAO-A}$. When $\text{MAO-A}$ is inhibited, ingested tyramine enters systemic circulation, crosses into peripheral sympathetic nerve terminals via NET, and forcefully displaces massive quantities of norepinephrine into the synaptic cleft. This triggers a severe Hypertensive Crisis (paroxysmal malignant hypertension, severe occipital headache, dilated pupils, stroke, and intracranial hemorrhage). Patients must adhere to a strict low-tyramine diet and undergo a mandatory 2-week washout period before switching between MAOIs and other serotonergic medications.
• Atypical Antidepressants:
  • Bupropion (Wellbutrin): A Norepinephrine-Dopamine Reuptake Inhibitor (NDRI). Uniquely lacks serotonergic activity, causing zero sexual dysfunction and no weight gain (frequently prescribed to treat SSRI-induced sexual dysfunction). However, it lowers the seizure threshold in a dose-dependent manner and is strictly contraindicated in patients with Bulimia Nervosa or Anorexia Nervosa due to an elevated risk of grand mal seizures.
  • Mirtazapine (Remeron): An antagonist at central presynaptic $\alpha_2$-adrenergic autoreceptors and heteroreceptors, enhancing noradrenergic and serotonergic transmission, while blocking postsynaptic $5\text{-HT}_2$ and $5\text{-HT}_3$ receptors. Highly potent $H_1$ histamine receptor antagonism causes marked sedation and appetite stimulation / weight gain (clinically useful for depressed geriatric patients with severe insomnia and cachexia).

2. Anxiolytics, Sedative-Hypnotics, and Mood Stabilizers

The GABAA Receptor Complex and Anxiolytic Electrophysiology

The $\text{GABA}_\text{A}$ receptor is a pentameric ligand-gated ion channel composed of protein subunits arranged around a central chloride ($Cl^-$) ion pore. When the primary inhibitory neurotransmitter $\gamma$-aminobutyric acid (GABA) binds to the receptor, the channel pore opens, allowing negatively charged chloride ions to flux down their electrochemical gradient into the neuron. This produces membrane hyperpolarization, driving the resting membrane potential further away from the action potential firing threshold and exerting immediate central nervous system inhibition.

                                  [ The GABAA Receptor Complex ]
                                                │
        ┌───────────────────────────────────────┴───────────────────────────────────────┐
        ▼                                                                               ▼
[ Benzodiazepines ]                                                             [ Barbiturates ]
- Positive Allosteric Modulator (PAM)                                           - Binds distinct channel site
- Increases FREQUENCY of channel opening                                        - Increases DURATION of channel opening
- GABA-dependent (safer in isolation)                                           - Directly opens channel at high doses (lethal)

• Benzodiazepines (Diazepam, Lorazepam, Alprazolam, Clonazepam):
  • Molecular Mechanism: Bind to an allosteric regulatory site situated at the interface between the $\alpha$ and $\gamma$ subunits of the $\text{GABA}_\text{A}$ receptor. They do not open the chloride channel directly; instead, they function as Positive Allosteric Modulators (PAMs), enhancing GABA's affinity for its binding site and increasing the FREQUENCY of chloride channel opening in the presence of GABA.
  • Clinical Profile: Rapid anxiolytic, sedative, muscle-relaxant, and anticonvulsant properties. However, chronic administration triggers rapid pharmacodynamic tolerance and physiological dependence. Abrupt cessation precipitates severe, potentially fatal withdrawal syndromes (rebound anxiety, autonomic hyperactivity, delirium tremens, grand mal seizures). Combined ingestion with other CNS depressants (alcohol, barbiturates, opioids) produces synergistic respiratory depression and fatal coma.
  • Antidote: Flumazenil, a competitive antagonist at the benzodiazepine binding site (used cautiously due to risk of inducing acute withdrawal seizures in dependent individuals).
• Barbiturates (Phenobarbital, Secobarbital, Amobarbital):
  • Molecular Mechanism: Bind to a distinct site on the $\text{GABA}_\text{A}$ complex and increase the DURATION of chloride channel opening. Crucially, at high concentrations, barbiturates can directly open the chloride channel in the complete absence of GABA (GABA-mimetic action).
  • Clinical Profile: Exceptionally narrow therapeutic index and high overdose lethality. Rapid tolerance develops to sedative effects without a corresponding increase in the lethal respiratory arrest threshold. Largely superseded by benzodiazepines in clinical practice.
• Buspirone (BuSpar):
  • Mechanism: A non-sedating anxiolytic with zero affinity for $\text{GABA}_\text{A}$ receptors. Acts as a high-affinity Partial Agonist at presynaptic and postsynaptic $5\text{-HT}_{1\text{A}}$ receptors.
  • Clinical Profile: Possesses zero sedative properties, zero cognitive impairment, zero abuse liability, zero physical dependence, and no cross-tolerance with benzodiazepines. However, it requires 2 to 4 weeks of daily administration to achieve therapeutic efficacy; effective for Generalized Anxiety Disorder, but completely ineffective for acute panic attacks.

Mood Stabilizers for Bipolar Disorder

• Lithium Carbonate Dynamics: Gold standard first-line maintenance therapy for Bipolar I Disorder; uniquely demonstrated to reduce suicide mortality in bipolar patients. Because lithium is filtered and reabsorbed by the proximal renal tubules in direct competition with sodium, volume depletion, hyponatremia, or NSAID use dramatically elevates lithium blood levels, triggering severe neurotoxicity.

3. Antipsychotic Medications: Typicals, Atypicals, and Neurological Adverse Effects

Antipsychotics (neuroleptics) treat schizophrenia, bipolar mania, and psychotic mood disorders. Their clinical and neurological profiles are dictated by their actions across the brain's four primary dopaminergic tracts.

                                [ Four Primary Dopamine Pathways ]
                                                │
     ┌──────────────────┬───────────────────────┴───────────────────────┬──────────────────┐
     ▼                  ▼                                               ▼                  ▼
[ Mesolimbic Tract ] [ Mesocortical Tract ]                           [ Nigrostriatal ]  [ Tuberoinfundibular ]
- VTA ──> Nucleus    - VTA ──> Prefrontal Cortex                      - Substantia Nigra - Hypothalamus ──>
  Accumbens          - Hypoactivity mediates Negative                   ──> Striatum       Pituitary
- Hyperactivity        & Cognitive symptoms                           - D2 blockade      - D2 blockade disinhibits
  mediates Positive  - FGAs worsen or fail to treat                     induces EPS        prolactin ──>
  symptoms           - SGAs (5-HT2A block) improve                      & Tardive Dys.     Hyperprolactinemia

First-Generation Antipsychotics (FGAs / Typicals)

• Compounds: High-potency (Haloperidol, Fluphenazine) vs. Low-potency (Chlorpromazine, Thioridazine).
• Mechanism: Potent competitive antagonists of Dopamine $\text{D}_2$ Receptors, particularly within the mesolimbic tract. Highly effective in extinguishing positive psychotic symptoms (auditory hallucinations, persecutory delusions, thought broadcasting), but largely ineffective for negative symptoms (avolition, flat affect, alogia).
• Extrapyramidal Symptoms (EPS): Caused by profound $\text{D}_2$ receptor blockade within the nigrostriatal pathway:
  1. Acute Dystonia: Develops within hours to days. Sustained, painful involuntary muscle spasms, characteristically manifesting as retrocollis/torticollis (neck twisting), oculogyric crisis (upward deviation of the eyes), or laryngeal spasms; treated emergently with parenteral anticholinergics (benztropine) or antihistamines (diphenhydramine).
  2. Akathisia: Develops within days to weeks. Intense, intolerable subjective motor restlessness and an overwhelming urge to move (pacing, rocking, inability to sit still); highly distressing, frequently misdiagnosed as worsening psychotic agitation; treated with lipophilic beta-blockers (propranolol) or benzodiazepines.
  3. Parkinsonism (Pseudoparkinsonism): Develops within weeks to months. Resting "pill-rolling" tremor, cogwheel muscle rigidity, bradykinesia/akinesia, masked facial expression, and shuffling/festinating gait; treated with anticholinergic agents (benztropine).
  4. Tardive Dyskinesia (TD): Develops after prolonged, chronic exposure (months to years). Characterized by involuntary, repetitive, choreoathetoid movements of the tongue, face, and lips (lip smacking, tongue protrusion / "fly-catcher's tongue", grimacing, rapid eye blinking) and choreiform movements of the extremities and trunk. Caused by upregulation and post-synaptic supersensitivity of dopamine $\text{D}_2$ receptors in the striatum following long-term blockade. Often irreversible; anticholinergic drugs worsen TD. Evaluated via the Abnormal Involuntary Movement Scale (AIMS); treated by switching to clozapine or administering vesicular monoamine transporter 2 (VMAT2) inhibitors (valbenazine, deutetrabenazine).
• Neuroleptic Malignant Syndrome (NMS): A rare, idiosyncratic, life-threatening neurological emergency precipitated by acute dopamine blockade. Characterized by the diagnostic tetrad ("FEVER"):
  • Fever: Severe hyperthermia ($> 104^\circ\text{F} / 40^\circ\text{C}$).
  • Encephalopathy: Acute delirium, altered mental status, stupor, coma.
  • Vital Sign Instability: Autonomic storm—tachycardia, labile blood pressure, profuse diaphoresis, tachypnea.
  • Elevated Enzymes: Marked elevation in serum Creatine Kinase (CK) and myoglobin secondary to severe rhabdomyolysis (muscle breakdown), posing an acute risk for myoglobinuric renal failure.
  • Rigidity: Generalized, severe "lead-pipe" muscle rigidity.
  • Management: Immediate cessation of all antipsychotics, emergency ICU care, aggressive cooling, and administration of dopamine agonists (bromocriptine) or peripheral muscle relaxants (dantrolene).

Second-Generation Antipsychotics (SGAs / Atypicals)

• Compounds: Clozapine, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole.
• Mechanism: Dual Dopamine $\text{D}_2$ and Serotonin $5\text{-HT}_{2\text{A}}$ Receptor Antagonism. $5\text{-HT}_{2\text{A}}$ antagonism stimulates dopamine release in the nigrostriatal pathway (dramatically mitigating EPS and TD risk) and in the prefrontal cortex (improving negative and cognitive symptoms). Aripiprazole acts uniquely as a $\text{D}_2$ partial agonist (functional dopamine stabilizer).
• Metabolic Syndrome: While SGAs minimize neurological EPS, they carry high risks for Metabolic Syndrome (marked weight gain, dyslipidemia, insulin resistance, type 2 diabetes mellitus, and cardiovascular disease). Highest metabolic risk: Olanzapine and Clozapine. Lowest metabolic risk: Ziprasidone and Aripiprazole.
• Clozapine (Clozaril) and Agranulocytosis:
  • The gold standard for treatment-resistant schizophrenia (failure of $\ge 2$ adequate antipsychotic trials) and reducing suicide risk in psychotic patients. Uniquely demonstrates virtually zero EPS and almost never causes tardive dyskinesia.
  • Black Box Warning: Agranulocytosis: A life-threatening idiosyncratic destruction of bone marrow granulocyte precursors, resulting in a precipitous depletion of the Absolute Neutrophil Count (ANC $< 500/\mu\text{L}$) in $\approx 1\%$ of patients, leaving them vulnerable to fatal septicemia.
  • ANC Monitoring: The prescribing information still directs regular absolute neutrophil count tracking (weekly for the first 6 months, every 2 weeks for the next 6 months, and monthly thereafter). The FDA ended the separate Clozapine REMS registry in 2025 (it stopped expecting REMS participation in February 2025 and formally removed the program in June 2025), so pharmacies no longer have to verify ANC results through a registry before dispensing. Other risks: myocarditis, paralytic ileus (constipation), and lowering of the seizure threshold.

4. Somatic and Neuromodulatory Treatments

Neuromodulatory interventions alter neural circuit firing through physical, electromagnetic, or surgical energy delivery, offering critical alternatives for severe, medication-resistant psychiatric conditions.

                                  [ Neuromodulatory Treatments ]
                                                │
     ┌──────────────────┬───────────────────────┴───────────────────────┬──────────────────┐
     ▼                  ▼                                               ▼                  ▼
[ Electroconvulsive ]  [ Repetitive TMS ]                             [ Deep Brain ]     [ Vagus Nerve ]
  Therapy (ECT)          (rTMS)                                         Stimulation (DBS)  Stimulation (VNS)
- Generalized seizure  - Non-invasive magnetic                        - Implanted deep   - Left vagus nerve
  under anesthesia       pulses over dlPFC                              electrodes         stimulation
- Highest efficacy for - No seizure or anesthesia                     - Subgenual Cing.  - Projects to NTS,
  treatment-resistant  - Spares memory & cognition                      (Area 25) for      locus coeruleus,
  depression & catatonia                                                refractory MDD     & raphe nuclei

Electroconvulsive Therapy (ECT)

• Procedure and Mechanism: Conducted under general anesthesia (methohexital) and a depolarizing neuromuscular paralytic (succinylcholine) to prevent peripheral musculoskeletal injury, with continuous EEG/ECG monitoring. Brief electrical pulses are delivered across the scalp to elicit a therapeutic generalized tonic-clonic cerebral seizure lasting at least $20\text{--}30$ seconds on motor observation ($\ge 25\text{--}30$ seconds on EEG). A standard acute course comprises 6 to 12 sessions administered 2–3 times per week.
• Clinical Efficacy and Indications: Exhibits the highest acute response rate ($70\text{--}85\%$) of any intervention for severe, treatment-resistant major depressive disorder, psychotic depression, acute catatonia, and patients with immediate, high suicidal lethality who cannot wait weeks for pharmacotherapy.
• Adverse Cognitive Effects: Post-ictal delirium and confusion; Retrograde Amnesia (loss of memories established prior to ECT, characteristically demonstrating a temporal gradient where memories closest to treatment are most vulnerable; permanent gaps for events immediately surrounding treatment may persist); and Anterograde Amnesia (temporary inability to retain newly learned information, typically resolving fully within weeks to months following treatment cessation).
• Electrode Placement: Bilateral (Bifrontotemporal) ECT provides slightly faster and more robust remission but causes significantly greater retrograde memory impairment; Right Unilateral (RUL) ultrabrief pulse ECT substantially spares cognitive and memory functions while retaining robust clinical efficacy.

Repetitive Transcranial Magnetic Stimulation (rTMS)

• Mechanism: A non-invasive neuromodulatory intervention utilizing an insulated electromagnetic coil placed against the scalp. Rapidly alternating electric currents within the coil generate focal, pulsating magnetic fields (up to $1.5\text{--}3.0\text{ Tesla}$) that pass unattenuated through the cranium, inducing localized electrical currents in underlying cortical pyramidal neurons.
• Protocol: FDA-approved for treatment-resistant major depression. Standard treatment delivers high-frequency ($10\text{--}20\text{ Hz}$, excitatory) rTMS to the Left Dorsolateral Prefrontal Cortex (dlPFC) (which is metabolically hypoactive in depression), or low-frequency ($1\text{ Hz}$, inhibitory) rTMS to the Right dlPFC.
• Clinical Advantages: Requires no general anesthesia, induces no seizures, causes zero cognitive or memory deficits, and permits immediate return to daily activities. Primary adverse effects are localized scalp discomfort and mild tension headaches; seizure induction risk is exceptionally rare ($< 0.1\%$).

Deep Brain Stimulation (DBS) and Vagus Nerve Stimulation (VNS)

• Deep Brain Stimulation (DBS): An invasive neurosurgical procedure involving the stereotactic implantation of bilateral quadripolar electrodes directly into deep subcortical structures, connected via subcutaneous extension wires to a pulse generator implanted beneath the clavicle:
  • Obsessive-Compulsive Disorder (OCD): FDA-approved (under Humanitarian Device Exemption) targeting the anterior limb of the internal capsule (ALIC) / ventral striatum.
  • Treatment-Resistant Depression: Pioneered by Helen Mayberg, targeting the Subgenual Cingulate Cortex (Brodmann Area 25 / Cg25). Area 25 is hyperactive in treatment-resistant depression; continuous high-frequency stimulation suppresses this hyperactivity and normalizes frontolimbic connectivity.
• Vagus Nerve Stimulation (VNS): Surgical implantation of a stimulation lead wrapped around the left vagus nerve (Cranial Nerve X) in the neck, connected to a subcutaneous generator. Intermittent electrical pulses travel along vagal afferent fibers into the brainstem Nucleus Tractus Solitarius (NTS), projecting diffusely to the locus coeruleus and dorsal raphe nuclei. FDA-approved as an adjunctive long-term maintenance therapy for chronic, treatment-resistant depression.